argenx SE continued to build momentum towards its goal of treating 50,000 patients with its medicines by 2030 as both its pipeline and clinical development activities increased. By 30 June, the company’s lead product Vyvgart (efgartigimod), which was first approved in 2021, had already achieved three approved indications, and the company was conducting or making plans for registrational studies for two other products.